Malaysia Special Access Route for Unregistered Medical Devices

1. Key takeaways

An unregistered medical device can reach patients in Malaysia in defined circumstances through the Special Access Route, commonly abbreviated as SAR. The route is not a general discretion; it applies to identified scenarios in which the ordinary registration pathway would not serve the clinical need in time or at all. Those scenarios cover an immediate risk to the life or health of patients where no local alternative exists, compassionate use where there is no alternative treatment or where existing treatment has failed or is unsuitable, mitigation of a supply interruption affecting a comparable registered device, for example while a change or post-market action is under way, and novel devices supported by evidence of superior patient outcomes. Each scenario has its own justification logic, and the application must fit the one being relied on.

• SAR is an access channel, not a substitute for registration, and approval does not confer a registration certificate.
• Imports under SAR are normally approved on a per-occasion or per-scenario basis rather than as an ongoing authorisation.
• Long-term commercial supply still requires completion of the formal registration process.
• Applications are initiated locally by the AR or by the healthcare institution, not by the overseas manufacturer alone.
• A medical necessity justification and a risk control arrangement are required components of the application.
• The detailed document list and the approval criteria follow the MDA guidance in force at the time.
• Adverse events occurring under SAR remain reportable and should be recorded in the PMS ledger.

2. Legal basis

Beyond the SAR policy itself, section 77 of Act 737 empowers the Minister to exempt specified persons or devices from particular provisions by order published in the Gazette, on the basis of public health and safety interests. Temporary arrangements during major public health events have generally rested on this provision. The distinction between the two instruments matters. The SAR policy describes an access mechanism within the regulatory system, while section 77 provides a statutory exemption power that operates at the level of specific provisions. Circular 2/2018 Rev.2 is relevant as a legislative technique reference for related control policies, showing how exemption-style instruments have been structured, but it is not the instrument that authorises a routine SAR application. The registration obligation itself, from which SAR provides a time-limited departure, remains in Act 737, and SAR does not alter the status of that obligation for general supply.

3. Expert insights

The most common misunderstanding about SAR is that it functions as a fast-track registration. It does not. SAR authorises access to a specific device for a specific situation, usually for a defined occasion or period, and it leaves the registration status of the product unchanged. A hospital that obtains a SAR approval has permission to use or import the device in that context; it does not hold a registered product that can be supplied generally. Manufacturers who treat the approval as a market entry point tend to discover the limit when they attempt to expand supply, at which point the registration obligation reasserts itself with no time saved.

The scenarios themselves require different kinds of argument. Immediate risk to life or health depends on establishing both the urgency and the absence of a local alternative, which means the file must address what else is available in Malaysia and why it is insufficient. Compassionate use depends on the treatment history: either no alternative exists, or existing treatment has failed or is unsuitable for the patient concerned. Supply interruption mitigation depends on the status of a comparable registered device, for example where a change is in progress or a post-market action is affecting availability. The novel device scenario depends on evidence of superior patient outcomes, which is a higher evidentiary bar than the other three and should be planned accordingly.

For manufacturers based in China, three situations arise repeatedly in practice: urgent supply ahead of a hospital tender, first clinical use of an exclusive innovative device, and temporary bridging during a gap in the supply chain. Each has a different timeline logic, and in each case the practical constraint is the same, namely that the application is initiated locally. Confirming the SAR application materials with the AR in advance is what prevents a situation in which the clinical need is genuine but the paperwork cannot be assembled in time. The exercise is less about drafting a persuasive case than about having the medical necessity evidence and the risk control arrangements ready before the request arises.

4. Practical recommendations

• Identify which of the four SAR scenarios the request actually fits, and build the justification around that scenario rather than a general plea of clinical need.
• Confirm the SAR application materials with the AR before a clinical need arises, so that the file can be assembled under time pressure.
• Document the local alternatives and explain why they are insufficient where the immediate risk scenario is relied on.
• Record the treatment history where compassionate use is the basis, including prior treatment failure or unsuitability.
• Describe the supply interruption and the comparable registered device where that scenario is used, including the status of any change or post-market action.
• Prepare the risk control arrangements as a distinct section, since they are a required component rather than supporting background.
• Enter every SAR approval into the PMS ledger and treat adverse events under SAR as reportable, recognising that the record will be visible in later registration review.

5. Verification checklist

• □ Section 77 of Act 737 has been reviewed for the Ministerial exemption power and its public health and safety basis.
• □ The MDA SAR policy framework has been checked, with any interpretation of it identified as common industry reading.
• □ Circular 2/2018 Rev.2 has been consulted only as a legislative technique reference for related control policies.
• □ The application identifies the initiating local party, either the AR or the healthcare institution.
• □ The document list and approval criteria have been confirmed against the MDA guidance currently in force.
• □ SAR approvals and any associated adverse events are recorded in the PMS ledger.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Malaysia. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the MDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com